---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Limitations of current therapies"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Limitations of current therapies. Topics: Diminishing remission with each successive treatment step, Reanalysis of cumulative remission in the Sequenced Treatment Alternatives to Relieve Depression trial, Lower success of further antidepressant trials, Tolerability of adjunctive antipsychotics, and 6 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Limitations of current therapies

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

### Summary

In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/); [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf); [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/); [Spielmans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3595214/); [Tsai et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40197402/); [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf); [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf); [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/); [Jelovac et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799066/)

<a id="topic-2.2.2.1.9-2"></a>

### Diminishing remission with each successive treatment step

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.”
> “Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.2.1.9-3"></a>

### Reanalysis of cumulative remission in the Sequenced Treatment Alternatives to Relieve Depression trial

> “In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.”

Source: [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/)

<a id="topic-2.2.2.1.9-4"></a>

### Lower success of further antidepressant trials

> “The success of another course of antidepressant medications in TRD is much lower than in others with MDD; however, many patients with TRD are treated with additional trials of antidepressant medications.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.2.1.9-5"></a>

### Tolerability of adjunctive antipsychotics

> “Adjunctive strategies, especially with atypical antipsychotic agents (serotonin and dopamine activity modulators), have greater evidence for efficacy and shorter time to response or remission, but they generally have a greater side effect burden than antidepressant monotherapy”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “However, antipsychotic users had increased risk of all-cause mortality (hazard ratio 1.21; 95% CI 1.07-1.33).”
> “These findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression.”

Source: [Tsai et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40197402/)

<a id="topic-2.2.2.1.9-6"></a>

### Esketamine: certified settings and two-hour observation at each session

> “Healthcare settings must be certified in the program and ensure that SPRAVATO is: − Only dispensed and administered in healthcare settings.”
> “Because of the possibility of delayed or prolonged sedation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

### Ketamine and esketamine: treatment space, repeated visits, and regional access

> “Additionally, there are unique resource and feasibility challenges associated with administering these treatments, such as the need for intravenous access with ketamine infusions and the need for appropriate clinical treatment space and post-treatment monitoring for both ketamine and esketamine.”
> “These resource challenges are compounded by the lack of long term durability from these treatments, which necessitates repeated trips to a treatment facility for receiving ongoing maintenance doses in many cases.”
> “There is currently limited access in some regions (e.g., rural areas) for both treatments due to a lack of providers with adequate clinical resources, experience, and training.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.9-8"></a>

### Short duration of effect after ketamine

> “The effects of ketamine lasted no more than one week after treatment and clearly disappeared after two weeks.”

Source: [Dean et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434915/)

<a id="topic-2.2.2.1.9-9"></a>

### ECT: stigma, anaesthesia, cognitive effects, and relapse

> “However, the clinical use of ECT is often hindered by stigma, the need for general anaesthesia, concern about cognitive adverse effects, and high rates of relapse after acute treatment.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

> “There is a large variation in preferences for using ECT due to both risks and stigma associated with the treatment.”
> “The Work Group noted that resources, acceptability, and feasibility sometimes limit the ability to use this treatment and that certain areas will not have this treatment option.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.9-10"></a>

### Neuromodulation: availability, daily visits, and specialized personnel

> “because of feasibility issues, including limited availability (especially in the public health sector), patient burden (e.g., requiring daily clinic visits for rTMS), and the need for specialized personnel (e.g., anaesthesiologists for ECT).”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.9-11"></a>

### VNS: surgical implantation and adverse events

> “Evidence indicates a greater than 5% chance of significant adverse events for patients who have been implanted with VNS.”
> “Acceptability, resource availability, and risk of surgical complications are also considerations.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
